Medulloblastoma - Pipeline Review, H2 2017

Date: December 29, 2017
Pages: 197
Price:
US$ 2,000.00
License [?]:
Publisher: Global Markets Direct
Report type: Strategic Report
Delivery: E-mail Delivery (PDF)
ID: MF7DB68C5DBEN
Leaflet:

Download PDF Leaflet

Medulloblastoma - Pipeline Review, H2 2017
Medulloblastoma - Pipeline Review, H2 2017

SUMMARY

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Medulloblastoma - Pipeline Review, H2 2017, provides an overview of the Medulloblastoma (Oncology) pipeline landscape.

Medulloblastoma is the most common malignant brain tumor in children. Medulloblastoma by definition occur in the cerebellum, which is the part of brain located at the base of the skull, just above the brainstem. Symptoms associated with a medulloblastoma include headaches in the morning that improve as the day goes on, recurrent vomiting and difficulty walking and with balance. Medulloblastoma can spread to other areas of the central nervous system. Treatment includes options such as chemotherapy, surgery, biological therapy and radiation therapy.

REPORT HIGHLIGHTS

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Medulloblastoma - Pipeline Review, H2 2017, provides comprehensive information on the therapeutics under development for Medulloblastoma (Oncology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Medulloblastoma (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Medulloblastoma and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies/Universities/Institutes, the molecules developed by Companies in Phase II, Phase I and Preclinical stages are 8, 3 and 15 respectively. Similarly, the Universities portfolio in Phase II and Preclinical stages comprises 1 and 4 molecules, respectively.

Medulloblastoma (Oncology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

SCOPE
  • The pipeline guide provides a snapshot of the global therapeutic landscape of Medulloblastoma (Oncology).
  • The pipeline guide reviews pipeline therapeutics for Medulloblastoma (Oncology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Medulloblastoma (Oncology) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Medulloblastoma (Oncology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Medulloblastoma (Oncology)
REASONS TO BUY
  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Medulloblastoma (Oncology).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Medulloblastoma (Oncology) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.


NOTE: Out of security concerns Global Markets Direct requires using corporate email address.
Introduction
Global Markets Direct Report Coverage
Medulloblastoma - Overview
Medulloblastoma - Therapeutics Development
Pipeline Overview
Pipeline by Companies
Pipeline by Universities/Institutes
Products under Development by Companies
Products under Development by Universities/Institutes
Medulloblastoma - Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Medulloblastoma - Companies Involved in Therapeutics Development
Bayer AG
Boehringer Ingelheim GmbH
Bristol-Myers Squibb Co
Celgene Corp
DelMar Pharmaceuticals Inc
Ignyta Inc
IMPACT Therapeutics Inc
Janpix Inc
Lipocure Ltd
MacroGenics Inc
Medicenna Therapeutics Corp
Millennium Pharmaceuticals Inc
NewLink Genetics Corp
Ono Pharmaceutical Co Ltd
Progenics Pharmaceuticals Inc
Stemline Therapeutics Inc
ThromboGenics NV
VBI Vaccines Inc
Vyriad Inc
Medulloblastoma - Drug Profiles
(topotecan hydrochloride + vincristine sulfate) - Drug Profile
afatinib dimaleate - Drug Profile
Bispecific Monoclonal Antibodies to Target IL13RA2 and CD3 for Oncology - Drug Profile
Bispecific Monoclonal Antibodies to Target ROR1 and CD3 for Oncology - Drug Profile
Cellular Immunotherapy for Oncology - Drug Profile
dianhydrogalactitol - Drug Profile
Edotreotide Labeled Yttrium 90 - Drug Profile
IMP-5471 - Drug Profile
indoximod - Drug Profile
ipilimumab + nivolumab - Drug Profile
irinotecan hydrochloride + TBio-02 - Drug Profile
LY-5 - Drug Profile
MDNA-55 - Drug Profile
nifurtimox - Drug Profile
nivolumab - Drug Profile
Oncolytic Virus to Target CD46 and SLC5A5 for Brain Tumor and Recurrent Medulloblastoma - Drug Profile
p28 - Drug Profile
pomalidomide - Drug Profile
pyrvinium pamoate - Drug Profile
sapanisertib - Drug Profile
SL-301 - Drug Profile
Small Molecule to Antagonize Smoothened Homolog for Medulloblastoma and Colon Cancer - Drug Profile
Small Molecules to Inhibit STAT3 and STAT5 for Oncology - Drug Profile
Small Molecules to Inhibit STAT3 for Medulloblastoma and Glioblastoma Multiforme - Drug Profile
Small Molecules to Inhibit STAT5 for Oncology - Drug Profile
taladegib - Drug Profile
THR-317 - Drug Profile
Trilexium - Drug Profile
Vaccine to Target CMV Antigen for Central Nervous System Cancer - Drug Profile
VBI-1901 - Drug Profile
VMY-1103 - Drug Profile
Medulloblastoma - Dormant Projects
Medulloblastoma - Product Development Milestones
Featured News & Press Releases
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

LIST OF TABLES

Number of Products under Development for Medulloblastoma, H2 2017
Number of Products under Development by Companies, H2 2017
Number of Products under Development by Companies, H2 2017 (Contd.1), H2 2017
Number of Products under Development by Universities/Institutes, H2 2017
Products under Development by Companies, H2 2017
Products under Development by Companies, H2 2017 (Contd.1), H2 2017
Products under Development by Universities/Institutes, H2 2017
Number of Products by Stage and Target, H2 2017
Number of Products by Stage and Target, H2 2017 (Contd.1), H2 2017
Number of Products by Stage and Mechanism of Action, H2 2017
Number of Products by Stage and Mechanism of Action, H2 2017 (Contd.1), H2 2017
Number of Products by Stage and Route of Administration, H2 2017
Number of Products by Stage and Molecule Type, H2 2017
Medulloblastoma - Pipeline by Bayer AG, H2 2017
Medulloblastoma - Pipeline by Boehringer Ingelheim GmbH, H2 2017
Medulloblastoma - Pipeline by Bristol-Myers Squibb Co, H2 2017
Medulloblastoma - Pipeline by Celgene Corp, H2 2017
Medulloblastoma - Pipeline by DelMar Pharmaceuticals Inc, H2 2017
Medulloblastoma - Pipeline by Ignyta Inc, H2 2017
Medulloblastoma - Pipeline by IMPACT Therapeutics Inc, H2 2017
Medulloblastoma - Pipeline by Janpix Inc, H2 2017
Medulloblastoma - Pipeline by Lipocure Ltd, H2 2017
Medulloblastoma - Pipeline by MacroGenics Inc, H2 2017
Medulloblastoma - Pipeline by Medicenna Therapeutics Corp, H2 2017
Medulloblastoma - Pipeline by Millennium Pharmaceuticals Inc, H2 2017
Medulloblastoma - Pipeline by NewLink Genetics Corp, H2 2017
Medulloblastoma - Pipeline by Ono Pharmaceutical Co Ltd, H2 2017
Medulloblastoma - Pipeline by Progenics Pharmaceuticals Inc, H2 2017
Medulloblastoma - Pipeline by Stemline Therapeutics Inc, H2 2017
Medulloblastoma - Pipeline by ThromboGenics NV, H2 2017
Medulloblastoma - Pipeline by VBI Vaccines Inc, H2 2017
Medulloblastoma - Pipeline by Vyriad Inc, H2 2017
Medulloblastoma - Dormant Projects, H2 2017

LIST OF FIGURES

Number of Products under Development for Medulloblastoma, H2 2017
Number of Products under Development by Companies, H2 2017
Number of Products under Development by Universities/Institutes, H2 2017
Number of Products by Top 10 Targets, H2 2017
Number of Products by Stage and Top 10 Targets, H2 2017
Number of Products by Top 10 Mechanism of Actions, H2 2017
Number of Products by Stage and Top 10 Mechanism of Actions, H2 2017
Number of Products by Top 10 Routes of Administration, H2 2017
Number of Products by Stage and Top 10 Routes of Administration, H2 2017
Number of Products by Top 10 Molecule Types, H2 2017
Number of Products by Stage and Top 10 Molecule Types, H2 2017

COMPANIES MENTIONED

Bayer AG
Boehringer Ingelheim GmbH
Bristol-Myers Squibb Co
Celgene Corp
DelMar Pharmaceuticals Inc
Ignyta Inc
IMPACT Therapeutics Inc
Janpix Inc
Lipocure Ltd
MacroGenics Inc
Medicenna Therapeutics Corp
Millennium Pharmaceuticals Inc
NewLink Genetics Corp
Ono Pharmaceutical Co Ltd
Progenics Pharmaceuticals Inc
Stemline Therapeutics Inc
ThromboGenics NV
VBI Vaccines Inc
Vyriad Inc
Skip to top


Ask Your Question

Medulloblastoma - Pipeline Review, H2 2017
Company name*:
Contact person*:
Phone/fax*:
Email*:
Request invoice
Your enquiry:
Please click on a Check Box below to confirm you are not a robot: